Tango Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Item 5.02 reports a departure of director or officer and changes to compensatory arrangements for certain officers effective 2026-07-31. Specific names, dollar amounts, share counts, and nature of departures are not provided in this filing header; full details would require review of the complete 8-K document text.
Why this rating
Leadership changes are routine at biotech firms. Without specifics on who departed or compensation amounts relative to $528M market cap, cannot assess materiality. Boilerplate 8-K Item 5.02 disclosure.
Extracted items
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.